Led by Chairman and CEO Joe Cosgrove, Pentec is a national provider of specialty infusion services to patients who require access to complex pharmaceutical products and services outside of the hospital setting.
For nearly 30 years, the company has been focused on providing innovative and proprietary nutritional therapies for patients suffering from chronic renal failure and highly complex therapies for patients with intrathecal pumps. It operates two primary divisions, Renal and Specialty Infusion.
The Renal division delivers proprietary and patent-pending therapies, including PROPLETE, which are designed to address issues of protein malnutrition in patients suffering from End Stage Renal Disease. The Joint-Commissioned-accredited SI division provides pain and spasticity management home infusion therapy.
Pentec employs nearly 300 people and is headquartered in Boothwyn, Pennsylvania.
NEP will help Pentec continue to grow both organically through increased penetration within its markets, and through acquisitions of companies in both existing and adjacent markets.
Additional financing for this transaction was provided by Norwest Mezzanine Partners, Madison Capital Funding, Golub Capital, Zions Bank, and CIT Group.